|
|
|
Volumn 45, Issue MAY., 1999, Pages 1191-1193
|
|
Raloxifene: Designer estrogen for preventing postmenopausal osteoporosis. Should it be used preferentially over estrogen and bisphosphonates?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALENDRONIC ACID;
BISPHOSPHONIC ACID DERIVATIVE;
CHOLESTEROL;
ESTROGEN;
ETIDRONIC ACID;
LOW DENSITY LIPOPROTEIN;
PLACEBO;
RALOXIFENE;
ADULT;
BONE ATROPHY;
BONE DENSITY;
CHOLESTEROL BLOOD LEVEL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOUBLE BLIND PROCEDURE;
ESTROGEN DEFICIENCY;
HUMAN;
HUMAN EXPERIMENT;
MASTALGIA;
NORMAL HUMAN;
NOTE;
PATHOPHYSIOLOGY;
POSTMENOPAUSE OSTEOPOROSIS;
RANDOMIZED CONTROLLED TRIAL;
VAGINA BLEEDING;
BONE DENSITY;
CHOLESTEROL;
CHOLESTEROL, HDL;
CHOLESTEROL, LDL;
DOUBLE-BLIND METHOD;
ESTROGEN ANTAGONISTS;
ESTROGENS;
EVALUATION STUDIES;
FEMALE;
HUMANS;
MIDDLE AGED;
OSTEOPOROSIS, POSTMENOPAUSAL;
PIPERIDINES;
PLACEBOS;
RALOXIFENE;
TIME FACTORS;
|
|
EID: 0033024569
PISSN: 0008350X
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (6)
|
|
References (4)
|
